Holen Sie sich die Stockscreener-App
26.06
1.01%
0.26
Handel nachbörslich:
26.06
Schlusskurs vom Vortag:
$25.80
Offen:
$26.19
24-Stunden-Volumen:
530.16K
Relative Volume:
0.40
Marktkapitalisierung:
$2.09B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-20.52
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
-0.84%
1M Leistung:
+2.44%
6M Leistung:
-7.92%
1J Leistung:
-17.09%
1-Tages-Spanne:
$25.23
$26.56
1-Wochen-Bereich:
$25.00
$26.59
52-Wochen-Spanne:
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
26.06 | 2.09B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.82 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
520.29 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.53 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
267.12 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Cancer Rates Are Surging in Young Adults -- Here's Where the Smart Money Is Going - KamloopsBCNow
Cancer Rates Are Surging in Young Adults — Here’s Where the Smart Money Is Going - Cantech Letter
CG Oncology (NASDAQ:CGON) Price Target Raised to $56.00 at Morgan Stanley - Defense World
Rhumbline Advisers Buys 5,673 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Trading 4.7% Higher After Analyst Upgrade - Defense World
CGON: Morgan Stanley Raises Price Target for CG Oncology | CGON Stock News - GuruFocus
CG Oncology price target raised to $56 from $52 at Morgan Stanley - TipRanks
August 15th Options Now Available For CG Oncology (CGON) - Nasdaq
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Cantor Fitzgerald Predicts CG Oncology FY2026 Earnings - Defense World
California State Teachers Retirement System Buys 20,763 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Squarepoint Ops LLC Makes New Investment in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference - Bluefield Daily Telegraph
CG Oncology Brings Breakthrough Bladder Cancer Treatment to Goldman Sachs Healthcare Conference - Stock Titan
Ameriprise Financial Inc. Grows Stock Holdings in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Promising Market Position and Investment Opportunity: CG Oncology’s Creto in NMIBC Treatment - TipRanks
CG Oncology, Inc. (NASDAQ:CGON) Position Reduced by Nuveen Asset Management LLC - Defense World
BNP Paribas Financial Markets Lowers Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CG Oncology’s SWOT analysis: bladder cancer treatment stock shows promise amid competition - Investing.com
Bank of America Corp DE Has $6.01 Million Stake in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
Millennium Management LLC Invests $7.14 Million in CG Oncology, Inc. (NASDAQ:CGON) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 1,026 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success - MSN
Deutsche Bank AG Acquires 13,589 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology (NASDAQ:CGON) Given New $52.00 Price Target at Morgan Stanley - Defense World
CGON Stock Rating Maintained by Morgan Stanley Despite Price Target Cut | CGON Stock News - GuruFocus
Cantor Fitzgerald Lowers Earnings Estimates for CG Oncology - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Position Boosted by Northern Trust Corp - Defense World
Q2 Earnings Forecast for CG Oncology Issued By HC Wainwright - Defense World
CG Oncology to Participate in the 2025 RBC Capital Markets Global Healthcare Conference - The Manila Times
Leading Bladder Cancer Drug Developer CG Oncology Takes Stage at Major RBC Healthcare Conference - Stock Titan
Analysts Are Bullish on These NA Stocks: American Healthcare REIT, Inc. (AHR), CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Shares Gap Down on Disappointing Earnings - Defense World
Decoding CG Oncology Inc (CGON): A Strategic SWOT Insight - GuruFocus
CG Oncology reports Q1 EPS (45c), consensus (37c) - TipRanks
CGON Q1 Revenue Falls Short; Advances in Bladder Cancer Therapy - GuruFocus
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates - ADVFN
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
CG Oncology Q1 Loss Widens, Revenue Falls - marketscreener.com
CG Oncology, Inc. SEC 10-Q Report - TradingView
CG Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Here Are Reasons Why Cg Oncology Inc (NASDAQ: CGON) Is A Great Choice Now - Stocksregister
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology (NASDAQ:CGON) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cg Oncology Inc-Aktie (CGON) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| POST LEONARD E | Director |
May 21 '25 |
Sale |
28.00 |
1,000 |
28,000 |
0 |
| POST LEONARD E | Director |
Apr 28 '25 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Apr 28 '25 |
Sale |
30.76 |
1,000 |
30,760 |
0 |
| POST LEONARD E | Director |
Mar 17 '25 |
Option Exercise |
0.60 |
1,000 |
600 |
1,000 |
| POST LEONARD E | Director |
Mar 17 '25 |
Sale |
28.00 |
1,000 |
28,000 |
0 |
1.06%
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):